Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Aegera began an open-label, Hong Kong Phase II trial to evaluate Nexavar sorafenib with or without AEG35156 in 50 patients. Bayer AG (Xetra:BAY, Leverkusen, Germany) and Onyx Pharmaceuticals Inc. (...